Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

Exclusion Criteria

• •Women of child bearing potential who are pregnant, breastfeeding or not using effective contraceptives
• •Known hypersensitivity to Pravastatin or any of its components
• •Have a history of homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia
• •Significant medical illness
• •Known serious conditions, e.g. serum creatine kinase(CK)levels 2.5 times upper limit of normal
• •Subjects being treated with drugs influence serum lipid concentrations
• •Subjects who have cancer or been receiving the cancer chemotherapy